New drugs ease itch for patients whose current treatment fails

Many people with primary biliary cholangitis struggle with relentless itching. Standard treatment often stops working. A large review looked at six hundred sixty patients who had an inadequate response to ursodeoxycholic acid. The team tested three new medicines called PPAR agonists against a placebo. These drugs include bezafibrate, elafibranor, and seladelpar. The goal was to see if they could help control the worst symptom: itch. The results were clear. At three, six, and twelve months, the new drugs significantly reduced itch scores compared to the placebo. Patients felt relief when they took these medications. Safety signals were not reported in the study data. No serious adverse events or discontinuations were noted. However, the study could not prove these drugs improved overall quality of life. The certainty around this specific outcome was lower. This does not mean the drugs are unsafe, just that the full picture of daily life improvement needs more proof. Future trials should focus on validated symptom-focused endpoints to better understand patient experiences.